Clinical Trial: Testing Zanubrutinib and Tislelizumab as Well as Standard of Care for the Treatment of Patients With Progressive Lymphoma Post Anti-CD19 CAR-T Cell Therapy

U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT06919705) titled 'Testing Zanubrutinib and Tislelizumab as Well as Standard of Care for the Treatment of Patients With Progressive Lymphoma Post Anti-CD19 CAR-T Cell Therapy' on April 02.

Brief Summary: This study is designed to see how well two new drugs work, either alone or with the usual treatment, for patients whose lymphoma (a type of cancer) has gotten worse after they've already received a special type of immune therapy called anti-CD19 CAR-T cell therapy. It's a planned, multi-site clinical trial. This means that patients from several different medical centers will be involved in the study.

The study will test two specific drugs:

Zanubrut...